BIOPHARMA
By
Can Revolution Medicines and Iambic’s AI Alliance Accelerate the Discovery of Next-Gen Cancer Drugs Targeting RAS Mutations?
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is turning to artificial…
Can Johnson & Johnson’s 6-Point AI Strategy Revolutionize Surgery, Drug Discovery, and Global Patient Care?
Key Highlights From Experimentation to Execution: Focused AI for Measurable OutcomesAfter piloting 900+ generative AI use cases, Johnson…
Is AstraZeneca’s $20M AI Hub in Bengaluru the Catalyst for 20 New Medicines by 2030?
Key Highlights Strategic Investment to Scale AI-Driven InnovationAstraZeneca has inaugurated a state-of-the-art Global Hub in Bengaluru with an…
Can Lisata Therapeutics and GATC Health’s AI Breakthrough Redefine Drug Discovery and Tackle the Opioid Crisis in Just One Year?
Key Highlights AI-Powered Drug Discovery Moves Toward the Clinic with OUD FocusLisata Therapeutics and GATC Health have expanded…
Can AstraZeneca’s $50B US Investment and Eli Lilly’s $27B Manufacturing Expansion Reshape the Future of American Biopharma?
Key Highlights Virginia Bets Big on Biopharma GrowthVirginia lawmakers have approved significant development packages to draw two of…
Can Cambridge and A*STAR’s New AI Digital Twin Platform Transform $50Bn Pharma Manufacturing Efficiency Landscape?
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…
